Key result
Peptide-supercharged platelets improve post-myocardial infarction cardiac outcomes in preclinical evaluation.
Why the study?
Survivors of acute myocardial infarction face an elevated risk of recurrent MI and heart failure driven by inappropriate healing and fibrosis of ischemic tissue.
Answers are grounded in this paper and cite their sources.
Should not yet change post-MI care; hypothesis-generating for peptide-supercharged platelet therapies in cardiac repair.
Myocardial infarction (MI) remains one of the most common causes of death worldwide. Although 70% of MI sufferers survive the acute episode, they are left with an elevated risk of a subsequent MI and developing heart failure, due to inappropriate healing of the ischaemic tissue, particularly leading to fibrosis (scarring). Post-MI, a substantial inflammatory response ensues to clear necrotic cardiomyocytes and damaged extracellular matrix, followed by inflammatory resolution in later stages of repair.
No takes yet. Share an insight, caveat, or question.
Furniss et al. (2026) studied Myocardial infarction. Peptide supercharged platelets was evaluated on Cardiac outcomes post-myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: